Business context and reporting period
SeaStar Medical Holding Corporation filed this Form 8-K on October 5, 2026, reporting a warrant exercise and related financing transaction that closed the same day. The filing reports a corporate event, not quarterly or annual operating results.
Transaction and key financial details
- Holders exercised prior warrants for 854,002 common shares at a reduced cash exercise price of $3.866 per share.
- The company received approximately $3.3 million in gross proceeds, before placement-agent fees and other offering expenses. Net proceeds were not specified; the company plans to use them for general corporate purposes, potentially including working capital and capital expenditures.
- In connection with the exercises, holders received immediately exercisable Series A and Series B warrants, each covering up to 854,002 shares, at $3.616 per share. Series A warrants expire five years after the resale registration statement becomes effective; Series B warrants expire after 18 months.
- The placement agent received warrants covering 59,780 shares, exercisable at $4.8325 per share, plus cash compensation: 7% of gross proceeds, a 1% management fee, $75,000 in non-accountable expenses, and a $15,950 clearing fee.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures, and no comparable-period financial results.
Changes and potential dilution
The transaction issued 854,002 shares upon exercise of the prior warrants and created potential issuance of up to 1,767,782 additional shares under the new holder warrants and placement-agent warrants. Actual future share issuance and proceeds from warrant exercises depend on whether the warrants are exercised.
Terms, outlook, and risks
- The company agreed to file a resale registration statement for the new warrant shares within 30 calendar days after October 2, 2026, and to use commercially reasonable efforts to obtain effectiveness within 60 days, or 90 days if the SEC conducts a full review.
- Until 30 days after closing, the company agreed, subject to exceptions, not to issue or announce other common stock or common-stock equivalents or file certain registration statements. It also agreed, subject to exceptions, not to enter into a variable-rate transaction for six months after closing.
- The new warrants, placement-agent warrants, and related shares were issued without registration under securities-law exemptions. The filing identifies the resale registration process as a condition relevant to resale.
- No financial guidance or operating outlook is provided.
Important facts for investors to verify
- The net cash proceeds after all fees and expenses, which the filing does not state.
- Whether and when the resale registration statement is filed and declared effective.
- The warrant terms and any exceptions to the issuance and variable-rate transaction restrictions in the filed exhibits.
- The potential dilution relative to the company’s shares outstanding and the likelihood of future warrant exercises.